Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated
macrophages (TAMs) contribute to tumour progression at different levels: by promoting …

Immunogenicity depends on two key factors: antigenicity and adjuvanticity. The presence of
exogenous or mutated antigens explains why infected cells and malignant cells can initiate …

Gastric cancers, with gastric adenocarcinoma (GAC) as the most common histological type,
impose a considerable global health burden. Although the screening strategies for early …

Immune checkpoint inhibitors, including those targeting CTLA‐4/B7 and the PD‐1/PD‐L1
inhibitory pathways, are now available for clinical use in cancer patients, with other …

Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly
2 decades ago through the identification of rare subpopulations of engrafting cells in …

The immunogenicity of cancer cells is an emerging determinant of anti‐cancer
immunotherapy. Beyond developing immunostimulatory regimens like dendritic cell‐based …

Morbidity and mortality associated with pediatric malignant primary brain tumors remain high
in the absence of effective therapies. Macrophage-mediated phagocytosis of tumor cells via …

The success of cancer immunotherapy has generated tremendous interest in identifying new
immunotherapeutic targets. To date, the majority of therapies have focussed on stimulating …

Chimeric antigen receptor (CAR) therapy targeting CD19 has yielded remarkable outcomes
in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute …

Abstract CD47, a “don't eat me” signal, is over-expressed on the surface of most tumors that
interacts with signal regulatory protein α (SIRPα) on phagocytic cells. By engaging SIRPα …